VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.

VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.

VivoSim Labs (VIVS) stock plunges over 25% on a $4M private placement priced at $0.85/share. Read about the dilutive offering.